The Latest Breaking News from Eli Lilly

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

The FDA fully approved Biogen Inc. but there are other companies with treatments in the pipeline

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

More evidence is needed if the treatment is to be approved for NHS use, England drugs watchdog says

More evidence is needed if the treatment is to be approved for NHS use, England drugs watchdog says

Nice says more evidence needed on effectiveness of tirzepatide, sold under brand name Mounjaro

The once-weekly jab would be offered to diabetic patients alongside diet and exercise,

Managing a distributed workforce is “the leadership challenge of our decade,” David Ricks, CEO of pharma giant Eli Lilly, said.

While tech layoffs make splashy headlines, other industries like health care, financial services, and education are eager to scoop up tech workers.